FibroGen (Mexico) Performance
| FGEN Stock | MXN 7.90 0.04 0.50% |
FibroGen has a performance score of 2 on a scale of 0 to 100. The firm shows a Beta (market volatility) of -0.54, which means possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning FibroGen are expected to decrease at a much lower rate. During the bear market, FibroGen is likely to outperform the market. FibroGen right now shows a risk of 5.29%. Please confirm FibroGen downside deviation, information ratio, and the relationship between the semi deviation and coefficient of variation , to decide if FibroGen will be following its price patterns.
Risk-Adjusted Performance
2 of 100
Weak | Strong |
Weak
Compared to the overall equity markets, risk-adjusted returns on investments in FibroGen are ranked lower than 2 (%) of all global equities and portfolios over the last 90 days. In spite of fairly weak basic indicators, FibroGen may actually be approaching a critical reversion point that can send shares even higher in December 2024. ...more
| Begin Period Cash Flow | 678.4 M | |
| Total Cashflows From Investing Activities | -427 M |
FibroGen |
FibroGen Relative Risk vs. Return Landscape
If you would invest 770.00 in FibroGen on August 31, 2024 and sell it today you would earn a total of 20.00 from holding FibroGen or generate 2.6% return on investment over 90 days. FibroGen is generating 0.1787% of daily returns and assumes 5.2895% volatility on return distribution over the 90 days horizon. Simply put, 47% of stocks are less volatile than FibroGen, and 97% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
FibroGen Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for FibroGen's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as FibroGen, and traders can use it to determine the average amount a FibroGen's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0338
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | FGEN | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 5.29 actual daily | 47 53% of assets are more volatile |
Expected Return
| 0.18 actual daily | 3 97% of assets have higher returns |
Risk-Adjusted Return
| 0.03 actual daily | 2 98% of assets perform better |
Based on monthly moving average FibroGen is performing at about 2% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of FibroGen by adding it to a well-diversified portfolio.
FibroGen Fundamentals Growth
FibroGen Stock prices reflect investors' perceptions of the future prospects and financial health of FibroGen, and FibroGen fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on FibroGen Stock performance.
| Return On Equity | -1.85 | |||
| Return On Asset | -0.27 | |||
| Profit Margin | (2.94) % | |||
| Operating Margin | (2.52) % | |||
| Current Valuation | 21.87 B | |||
| Shares Outstanding | 93.96 M | |||
| Price To Book | 54.45 X | |||
| Price To Sales | 231.63 X | |||
| Revenue | 235.31 M | |||
| EBITDA | (288.53 M) | |||
| Cash And Equivalents | 565.4 M | |||
| Cash Per Share | 6.56 X | |||
| Total Debt | 77.14 M | |||
| Debt To Equity | 15.10 % | |||
| Book Value Per Share | 0.28 X | |||
| Cash Flow From Operations | (82.23 M) | |||
| Earnings Per Share | (62.14) X | |||
| Total Asset | 773.82 M | |||
About FibroGen Performance
Evaluating FibroGen's performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if FibroGen has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if FibroGen has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company was incorporated in 1993 and is headquartered in San Francisco, California. FibroGen operates under Biotechnology classification in Mexico and is traded on Mexico Stock Exchange. It employs 461 people.Things to note about FibroGen performance evaluation
Checking the ongoing alerts about FibroGen for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for FibroGen help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| FibroGen had very high historical volatility over the last 90 days | |
| FibroGen has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the revenue of 235.31 M. Net Loss for the year was (290.02 M) with loss before overhead, payroll, taxes, and interest of (104.61 M). | |
| FibroGen has accumulated about 565.4 M in cash with (82.23 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 6.56. | |
| Over 79.0% of the company shares are owned by institutional investors |
- Analyzing FibroGen's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether FibroGen's stock is overvalued or undervalued compared to its peers.
- Examining FibroGen's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating FibroGen's management team can have a significant impact on its success or failure. Reviewing the track record and experience of FibroGen's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of FibroGen's stock. These opinions can provide insight into FibroGen's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for FibroGen Stock Analysis
When running FibroGen's price analysis, check to measure FibroGen's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy FibroGen is operating at the current time. Most of FibroGen's value examination focuses on studying past and present price action to predict the probability of FibroGen's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move FibroGen's price. Additionally, you may evaluate how the addition of FibroGen to your portfolios can decrease your overall portfolio volatility.